THINK Surgical Receives FDA 510(k) Clearance for TMINI Miniature Robotic System (TMINI 1.1)
THINK Surgical, Inc., an innovator in the field of orthopedic surgical robots, today announced that its TMINI® Miniature Robotic System (TMINI…
Author: Sigrun Pedersen
Vectorious Medical Technologies Announces First U.S. Patient Implanted with the V-LAP Left Atrial Pressure Sensor
A patient in Cincinnati has become the first in the United States to receive an innovative system that enables remote monitoring of his heart…
Experts Highlighted the Significance of Collaborative Healthcare Efforts Between India & Nigeria
In a world reshaping after the pandemic, healthcare has taken centre stage. Recently, the inaugural session of HEAL-Thy Samvad brought…
ORTHOINDY ANNOUNCES FIRST SPINE SURGERY UTILIZING SURGICAL THEATER’S XR TECHNOLOGY
OrthoIndy has announced a monumental step forward in surgical innovation by introducing augmented reality (AR) into surgical procedures. Distinguished spine…
From U.S. To South Korea: NuBest® Nutrition Expands Global Reach Through Online Retailer Coupang
NuBest® Nutrition proudly announces its global expansion into South Korea through a strategic partnership with Coupang Co., Ltd., the country’s…
LyGenesis Announces First Patient Dosed in its Phase 2a Clinical Trial of a First-in-Class Regenerative Cell Therapy for Patients with End-Stage Liver Disease
LyGenesis, a clinical-stage biotechnology company developing cell therapies for large unmet medical needs, announced today that the first patient has…
Galimedix Therapeutics presents new scientific data showing promising neuroprotective effects of GAL-201 for the treatment of Alzheimer’s disease at AD/PD™ 2024
Galimedix Therapeutics, Inc. (“Galimedix”), a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential…
vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to…
PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming…
Dragonfly Announces Clinical Collaboration Exploring Combinations Between Dragonfly’s DF1001 HER-2 TriNKET® and Gilead’s Trodelvy® in Two Cancer Indications
Dragonfly Therapeutics, Inc., a clinical-stage biotechnology company developing novel immunotherapies, today announced a new clinical collaboration designed to evaluate and…